OKYO Pharma Limited’s SEC filings document foreign-private-issuer reports on Form 6-K for a clinical-stage biopharmaceutical company with ordinary shares listed on Nasdaq. The disclosures cover urcosimod clinical and regulatory updates for neuropathic corneal pain, scientific-meeting materials, and descriptions of the company’s focus on inflammatory eye diseases and other ocular disorders.
The filing record also includes capital-structure and financing disclosures tied to Form F-3 registration statements, ordinary-share offerings, underwriter option exercises, and insider share purchases. These records present formal updates on the company’s securities, ownership activity, incorporated exhibits, and material announcements furnished under Exchange Act Rule 13a-16.
OKYO Pharma Ltd reports that Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen jointly beneficially own 4,058,445 Ordinary Shares, representing 7.9% of the class as of February 17, 2026.
The shares are held by Point72 Associates, LLC and the filing states Point72 Asset Management has shared voting and shared dispositive power over these 4,058,445 shares. The statement is submitted under a Joint Filing Agreement and lists the reporting parties' principal business address in Stamford, Connecticut.
OKYO Pharma Limited is offering 10,815,000 ordinary shares at $1.85 per share, raising about $20.0 million before underwriting fees. An additional 1,622,250 shares may be sold if the underwriters exercise their 30‑day option in full.
OKYO expects net proceeds of approximately $18.5 million, which it plans to use for clinical development of its product candidates, general corporate purposes and working capital. Shares outstanding will rise to 51,370,197 (or 52,992,447 if the option is fully exercised), creating immediate dilution of $1.54 per share compared with an as adjusted net tangible book value of $0.31.
The company is an emerging growth, clinical‑stage ophthalmology biotech focused on urcosimod for neuropathic corneal pain and dry eye disease. Its ordinary shares trade on the Nasdaq Capital Market under the symbol “OKYO,” and the offering is underwritten on a firm commitment basis by Piper Sandler.
OKYO Pharma Ltd disclosed that investor Jorey Chernett has filed Amendment No. 2 to a Schedule 13G reporting a significant stake in the company’s common shares. Chernett beneficially owns 3,802,194 shares, representing 9.45% of the outstanding common stock as of the event date.
The filing states that Chernett has sole voting and sole dispositive power over all reported shares, with no shared voting or dispositive authority. It also certifies that the securities were not acquired to change or influence control of OKYO Pharma Ltd, but rather as a passive investment.
OKYO Pharma Limited entered an underwriting agreement with Piper Sandler for an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share. The underwriter has a 30-day option to buy up to 1,622,250 additional shares at the same public price, less fees. Gross proceeds are expected to be approximately $20 million before discounts, commissions and expenses, with all shares sold by the company. Closing is expected on February 17, 2026, subject to customary conditions. OKYO plans to use net proceeds for clinical development of its product candidates, general corporate purposes and working capital. The deal is made under an effective Form F-3 registration, and an updated investor presentation is furnished to investors.
OKYO Pharma Limited is raising capital through an underwritten public offering of 10,815,000 ordinary shares at $1.85 per share, for expected gross proceeds of about $20 million before expenses and discounts. The underwriter also has a 30-day option to buy up to 1,622,250 additional shares, which would lift gross proceeds to roughly $23 million if fully exercised.
The company plans to use the net proceeds mainly to fund clinical development of its product candidates, along with general corporate purposes and working capital. OKYO, a clinical-stage biopharma focused on neuropathic corneal pain and inflammatory eye diseases, recently completed a successful phase 2 trial of its lead drug urcosimod and is planning a ~150-patient Phase 2b/3 study.
Dauntless Investment Group, LLC filed Amendment No. 3 to a Schedule 13G reporting a passive ownership position in OKYO Pharma Ltd. The firm reports beneficial ownership of 471,523 common shares, representing 1.17% of the class as of December 31, 2025.
Dauntless, a Delaware single family office/passive investor, reports no sole or shared voting power over OKYO shares. It has sole dispositive power over 360,352 shares and shared dispositive power over 111,171 shares, and certifies the holdings are not for changing or influencing control of OKYO Pharma.
Dauntless Investment Group, LLC filed Amendment No. 3 to a Schedule 13G reporting a passive ownership position in OKYO Pharma Ltd. The firm reports beneficial ownership of 471,523 common shares, representing 1.17% of the class as of December 31, 2025.
Dauntless, a Delaware single family office/passive investor, reports no sole or shared voting power over OKYO shares. It has sole dispositive power over 360,352 shares and shared dispositive power over 111,171 shares, and certifies the holdings are not for changing or influencing control of OKYO Pharma.
OKYO Pharma Limited intends to offer and sell its ordinary shares in an underwritten public offering, with all shares to be issued by the company. The company expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares sold.
The deal will be made under an effective Form F-3 shelf registration, with Piper Sandler & Co. as sole book-running manager, and is subject to market conditions. OKYO plans to use net proceeds mainly to fund clinical development of its product candidates, as well as for general corporate purposes and working capital.
OKYO Pharma Limited intends to offer and sell its ordinary shares in an underwritten public offering, with all shares to be issued by the company. The company expects to grant the underwriter a 30-day option to buy up to an additional 15% of the shares sold.
The deal will be made under an effective Form F-3 shelf registration, with Piper Sandler & Co. as sole book-running manager, and is subject to market conditions. OKYO plans to use net proceeds mainly to fund clinical development of its product candidates, as well as for general corporate purposes and working capital.
OKYO Pharma Limited is conducting a primary offering of ordinary shares on The Nasdaq Capital Market under its F-3 shelf registration. The shares will be sold through an underwritten public offering led by Piper Sandler, with an additional 30-day option for underwriters to buy more shares.
OKYO expects to use the net proceeds for clinical development of its product candidates, general corporate purposes and working capital. As an emerging growth company, it follows reduced reporting requirements and warns investors about high investment risk, potential dilution from this and future equity issuances, and the possibility of Nasdaq delisting if listing standards are not maintained.
OKYO Pharma Limited is conducting a primary offering of ordinary shares on The Nasdaq Capital Market under its F-3 shelf registration. The shares will be sold through an underwritten public offering led by Piper Sandler, with an additional 30-day option for underwriters to buy more shares.
OKYO expects to use the net proceeds for clinical development of its product candidates, general corporate purposes and working capital. As an emerging growth company, it follows reduced reporting requirements and warns investors about high investment risk, potential dilution from this and future equity issuances, and the possibility of Nasdaq delisting if listing standards are not maintained.
OKYO Pharma Limited has transitioned its at-the-market equity offering facility to Leerink Partners LLC, replacing its prior arrangement with B. Riley Securities. Leerink will act as exclusive sales agent, able to sell OKYO common shares into the market from time to time at prevailing prices.
The ATM program is intended to give OKYO ongoing access to equity capital, at the Company’s discretion and subject to market conditions, with Leerink earning a commission equal to 3.0% of gross proceeds from any shares sold. Management highlights this as enhancing financial flexibility to fund clinical development, including the lead candidate urcosimod for neuropathic corneal pain.